MEI Pharma, Inc. (NASDAQ:MEIP) is trading higher in the mid-session on Monday. Major Trigger: MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib Key Highlights: today...
